BioMimetic Therapeutics Rating Lowere...

BioMimetic Therapeutics Rating Lowered to Neutral at Summer Street

Separately, analysts at Zacks downgraded shares of BioMimetic Therapeutics from an "outperform" rating to a "neutral" rating in a research note to investors on Tuesday, January 8th.

Start the conversation, or

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

More from around the web